PTP4A3: Difference between revisions
m Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +) |
m →top: clean up, added underlinked tag using AWB |
||
Line 1: | Line 1: | ||
{{Underlinked|date=September 2017}} | |||
{{Infobox_gene}} | |||
'''Protein tyrosine phosphatase type IVA 3''' is an [[enzyme]] that in humans is encoded by the ''PTP4A3'' [[gene]].<ref name="entrez">{{cite web | title = Entrez Gene: PTP4A3 protein tyrosine phosphatase type IVA, member 3| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=11156| accessdate = }}</ref> | |||
}} | |||
'''Protein tyrosine phosphatase type IVA | |||
<!-- The PBB_Summary template is automatically maintained by Protein Box Bot. See Template:PBB_Controls to Stop updates. --> | <!-- The PBB_Summary template is automatically maintained by Protein Box Bot. See Template:PBB_Controls to Stop updates. --> | ||
{{PBB_Summary | {{PBB_Summary | ||
| section_title = | | section_title = | ||
| summary_text = The protein encoded by this gene belongs to a small class of prenylated protein tyrosine phosphatases (PTPs). PTPs are cell signaling molecules that play regulatory roles in a variety of cellular processes. This class of PTPs contain a PTP domain and a characteristic C-terminal prenylation motif. Studies of this class of PTPs in mice demonstrated that they were prenylated proteins in vivo, which suggested their association with cell plasma membrane. Overexpression of this gene in mammalian cells was reported to inhibit angiotensin-II induced cell calcium mobilization and promote cell growth. Two alternatively spliced variants exist.<ref name="entrez" | | summary_text = The protein encoded by this gene belongs to a small class of prenylated protein tyrosine phosphatases (PTPs). PTPs are cell signaling molecules that play regulatory roles in a variety of cellular processes. This class of PTPs contain a PTP domain and a characteristic C-terminal prenylation motif. Studies of this class of PTPs in mice demonstrated that they were prenylated proteins in vivo, which suggested their association with cell plasma membrane. Overexpression of this gene in mammalian cells was reported to inhibit angiotensin-II induced cell calcium mobilization and promote cell growth. Two alternatively spliced variants exist.<ref name="entrez" /> | ||
}} | }} | ||
==References== | ==References== | ||
{{reflist | {{reflist}} | ||
==Further reading== | ==Further reading== | ||
{{refbegin | 2}} | {{refbegin | 2}} | ||
{{PBB_Further_reading | {{PBB_Further_reading | ||
| citations = | | citations = | ||
*{{cite journal | | *{{cite journal |vauthors=Zeng Q, Hong W, Tan YH |title=Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1 |journal=Biochem. Biophys. Res. Commun. |volume=244 |issue= 2 |pages= 421–7 |year= 1998 |pmid= 9514946 |doi= 10.1006/bbrc.1998.8291 }} | ||
*{{cite journal | | *{{cite journal |vauthors=Dayton MA, Knobloch TJ |title=Multiple phosphotyrosine phosphatase mRNAs are expressed in the human lung fibroblast cell line WI-38 |journal=Receptors & signal transduction |volume=7 |issue= 4 |pages= 241–56 |year= 1998 |pmid= 9633825 |doi= }} | ||
*{{cite journal | author=Zeng Q | *{{cite journal | author=Zeng Q |title=Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome |journal=J. Biol. Chem. |volume=275 |issue= 28 |pages= 21444–52 |year= 2000 |pmid= 10747914 |doi= 10.1074/jbc.M000453200 |name-list-format=vanc| author2=Si X | author3=Horstmann H | display-authors=3 | last4=Xu | first4=Y | last5=Hong | first5=W | last6=Pallen | first6=CJ }} | ||
*{{cite journal | author=Matter WF |title=Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling |journal=Biochem. Biophys. Res. Commun. |volume=283 |issue= 5 |pages= 1061–8 |year= 2001 |pmid= 11355880 |doi= 10.1006/bbrc.2001.4881 |name-list-format=vanc| author2=Estridge T | author3=Zhang C | display-authors=3 | last4=Belagaje | first4=Rama | last5=Stancato | first5=Louis | last6=Dixon | first6=Jeff | last7=Johnson | first7=Brian | last8=Bloem | first8=Laura | last9=Pickard | first9=Todd }} | |||
*{{cite journal | author= | *{{cite journal | author=Saha S |title=A phosphatase associated with metastasis of colorectal cancer |journal=Science |volume=294 |issue= 5545 |pages= 1343–6 |year= 2001 |pmid= 11598267 |doi= 10.1126/science.1065817 |name-list-format=vanc| author2=Bardelli A | author3=Buckhaults P | display-authors=3 | last4=Velculescu | first4=VE | last5=Rago | first5=C | last6=St Croix | first6=B | last7=Romans | first7=KE | last8=Choti | first8=MA | last9=Lengauer | first9=C }} | ||
*{{cite journal |vauthors=Wang J, Kirby CE, Herbst R |title=The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis |journal=J. Biol. Chem. |volume=277 |issue= 48 |pages= 46659–68 |year= 2003 |pmid= 12235145 |doi= 10.1074/jbc.M206407200 }} | |||
*{{cite journal | author= | *{{cite journal | author=Strausberg RL |title=Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 26 |pages= 16899–903 |year= 2003 |pmid= 12477932 |doi= 10.1073/pnas.242603899 | pmc=139241 |name-list-format=vanc| author2=Feingold EA | author3=Grouse LH | display-authors=3 | last4=Derge | first4=JG | last5=Klausner | first5=RD | last6=Collins | first6=FS | last7=Wagner | first7=L | last8=Shenmen | first8=CM | last9=Schuler | first9=GD }} | ||
*{{cite journal | author=Pathak MK |title=Pentamidine is an inhibitor of PRL phosphatases with anticancer activity |journal=Mol. Cancer Ther. |volume=1 |issue= 14 |pages= 1255–64 |year= 2003 |pmid= 12516958 |doi= |name-list-format=vanc| author2=Dhawan D | author3=Lindner DJ | display-authors=3 | last4=Borden | first4=EC | last5=Farver | first5=C | last6=Yi | first6=T }} | |||
*{{cite journal | | *{{cite journal | author=Zeng Q |title=PRL-3 and PRL-1 promote cell migration, invasion, and metastasis |journal=Cancer Res. |volume=63 |issue= 11 |pages= 2716–22 |year= 2003 |pmid= 12782572 |doi= |name-list-format=vanc| author2=Dong JM | author3=Guo K | display-authors=3 | last4=Li | first4=J | last5=Tan | first5=HX | last6=Koh | first6=V | last7=Pallen | first7=CJ | last8=Manser | first8=E | last9=Hong | first9=W }} | ||
*{{cite journal | author= | *{{cite journal | author=Bardelli A |title=PRL-3 expression in metastatic cancers |journal=Clin. Cancer Res. |volume=9 |issue= 15 |pages= 5607–15 |year= 2004 |pmid= 14654542 |doi= |name-list-format=vanc| author2=Saha S | author3=Sager JA | display-authors=3 | last4=Romans | first4=KE | last5=Xin | first5=B | last6=Markowitz | first6=SD | last7=Lengauer | first7=C | last8=Velculescu | first8=VE | last9=Kinzler | first9=KW }} | ||
*{{cite journal | author=Kozlov G |title=Structural insights into molecular function of the metastasis-associated phosphatase PRL-3 |journal=J. Biol. Chem. |volume=279 |issue= 12 |pages= 11882–9 |year= 2004 |pmid= 14704153 |doi= 10.1074/jbc.M312905200 |name-list-format=vanc| author2=Cheng J | author3=Ziomek E | display-authors=3 | last4=Banville | first4=D | last5=Gehring | first5=K | last6=Ekiel | first6=I }} | |||
*{{cite journal | author= | *{{cite journal | author=Kim KA |title=Structure of human PRL-3, the phosphatase associated with cancer metastasis |journal=FEBS Lett. |volume=565 |issue= 1–3 |pages= 181–7 |year= 2004 |pmid= 15135076 |doi= 10.1016/j.febslet.2004.03.062 |name-list-format=vanc| author2=Song JS | author3=Jee J | display-authors=3 | last4=Sheen | first4=Mee Rie | last5=Lee | first5=Chulhyun | last6=Lee | first6=Tae Gyu | last7=Ro | first7=Seonggu | last8=Cho | first8=Joong Myung | last9=Lee | first9=Weontae }} | ||
*{{cite journal | author=Wu X |title=Phosphatase of Regenerating Liver-3 Promotes Motility and Metastasis of Mouse Melanoma Cells |journal=Am. J. Pathol. |volume=164 |issue= 6 |pages= 2039–54 |year= 2004 |pmid= 15161639 |doi= 10.1016/S0002-9440(10)63763-7| pmc=1615773 |name-list-format=vanc| author2=Zeng H | author3=Zhang X | display-authors=3 | last4=Zhao | first4=Y | last5=Sha | first5=H | last6=Ge | first6=X | last7=Zhang | first7=M | last8=Gao | first8=X | last9=Xu | first9=Q }} | |||
*{{cite journal | author= | *{{cite journal | author=Gerhard DS |title=The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC) |journal=Genome Res. |volume=14 |issue= 10B |pages= 2121–7 |year= 2004 |pmid= 15489334 |doi= 10.1101/gr.2596504 | pmc=528928 |name-list-format=vanc| author2=Wagner L | author3=Feingold EA | display-authors=3 | last4=Shenmen | first4=CM | last5=Grouse | first5=LH | last6=Schuler | first6=G | last7=Klein | first7=SL | last8=Old | first8=S | last9=Rasooly | first9=R }} | ||
*{{cite journal | author=Kato H |title=High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases |journal=Clin. Cancer Res. |volume=10 |issue= 21 |pages= 7318–28 |year= 2005 |pmid= 15534108 |doi= 10.1158/1078-0432.CCR-04-0485 |name-list-format=vanc| author2=Semba S | author3=Miskad UA | display-authors=3 | last4=Seo | first4=Y | last5=Kasuga | first5=M | last6=Yokozaki | first6=H }} | |||
*{{cite journal | author= | *{{cite journal | author=Li J |title=Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases |journal=Clin. Cancer Res. |volume=11 |issue= 6 |pages= 2195–204 |year= 2005 |pmid= 15788667 |doi= 10.1158/1078-0432.CCR-04-1984 |name-list-format=vanc| author2=Guo K | author3=Koh VW | display-authors=3 | last4=Tang | first4=JP | last5=Gan | first5=BQ | last6=Shi | first6=H | last7=Li | first7=HX | last8=Zeng | first8=Q }} | ||
*{{cite journal | author=Polato F |title=PRL-3 phosphatase is implicated in ovarian cancer growth |journal=Clin. Cancer Res. |volume=11 |issue= 19 Pt 1 |pages= 6835–9 |year= 2006 |pmid= 16203771 |doi= 10.1158/1078-0432.CCR-04-2357 |name-list-format=vanc| author2=Codegoni A | author3=Fruscio R | display-authors=3 | last4=Perego | first4=P | last5=Mangioni | first5=C | last6=Saha | first6=S | last7=Bardelli | first7=A | last8=Broggini | first8=M }} | |||
*{{cite journal | author= | *{{cite journal | author=Peng L |title=Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3 |journal=Biochem. Biophys. Res. Commun. |volume=342 |issue= 1 |pages= 179–83 |year= 2006 |pmid= 16472776 |doi= 10.1016/j.bbrc.2006.01.102 |name-list-format=vanc| author2=Jin G | author3=Wang L | display-authors=3 | last4=Guo | first4=Jianpin | last5=Meng | first5=Lin | last6=Shou | first6=Chengchao }} | ||
*{{cite journal | author=Rouleau C |title=Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function |journal=Mol. Cancer Ther. |volume=5 |issue= 2 |pages= 219–29 |year= 2006 |pmid= 16505094 |doi= 10.1158/1535-7163.MCT-05-0289 |name-list-format=vanc| author2=Roy A | author3=St Martin T | display-authors=3 | last4=Dufault | first4=MR | last5=Boutin | first5=P | last6=Liu | first6=D | last7=Zhang | first7=M | last8=Puorro-Radzwill | first8=K | last9=Rulli | first9=L }} | |||
*{{cite journal | author= | *{{cite journal | author=Radke I |title=Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer |journal=Br. J. Cancer |volume=95 |issue= 3 |pages= 347–54 |year= 2006 |pmid= 16832410 |doi= 10.1038/sj.bjc.6603261 | pmc=2360632 |name-list-format=vanc| author2=Götte M | author3=Kersting C | display-authors=3 | last4=Mattsson | first4=B | last5=Kiesel | first5=L | last6=Wülfing | first6=P }} | ||
}} | }} | ||
{{refend}} | {{refend}} | ||
{{PDB Gallery|geneid=11156}} | |||
{{ | {{Protein tyrosine phosphatases}} | ||
{{ | |||
<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. --> | |||
{{PBB_Controls | |||
| update_page = yes | |||
| require_manual_inspection = no | |||
| update_protein_box = yes | |||
| update_summary = yes | |||
| update_citations = yes | |||
}} |
Latest revision as of 01:24, 27 September 2017
This article needs more links to other articles to help integrate it into the encyclopedia. (September 2017) (Learn how and when to remove this template message) |
VALUE_ERROR (nil) | |||||||
---|---|---|---|---|---|---|---|
Identifiers | |||||||
Aliases | |||||||
External IDs | GeneCards: [1] | ||||||
Orthologs | |||||||
Species | Human | Mouse | |||||
Entrez |
|
| |||||
Ensembl |
|
| |||||
UniProt |
|
| |||||
RefSeq (mRNA) |
|
| |||||
RefSeq (protein) |
|
| |||||
Location (UCSC) | n/a | n/a | |||||
PubMed search | n/a | n/a | |||||
Wikidata | |||||||
|
Protein tyrosine phosphatase type IVA 3 is an enzyme that in humans is encoded by the PTP4A3 gene.[1]
The protein encoded by this gene belongs to a small class of prenylated protein tyrosine phosphatases (PTPs). PTPs are cell signaling molecules that play regulatory roles in a variety of cellular processes. This class of PTPs contain a PTP domain and a characteristic C-terminal prenylation motif. Studies of this class of PTPs in mice demonstrated that they were prenylated proteins in vivo, which suggested their association with cell plasma membrane. Overexpression of this gene in mammalian cells was reported to inhibit angiotensin-II induced cell calcium mobilization and promote cell growth. Two alternatively spliced variants exist.[1]
References
Further reading
- Zeng Q, Hong W, Tan YH (1998). "Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1". Biochem. Biophys. Res. Commun. 244 (2): 421–7. doi:10.1006/bbrc.1998.8291. PMID 9514946.
- Dayton MA, Knobloch TJ (1998). "Multiple phosphotyrosine phosphatase mRNAs are expressed in the human lung fibroblast cell line WI-38". Receptors & signal transduction. 7 (4): 241–56. PMID 9633825.
- Zeng Q, Si X, Horstmann H, et al. (2000). "Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome". J. Biol. Chem. 275 (28): 21444–52. doi:10.1074/jbc.M000453200. PMID 10747914.
- Matter WF, Estridge T, Zhang C, et al. (2001). "Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling". Biochem. Biophys. Res. Commun. 283 (5): 1061–8. doi:10.1006/bbrc.2001.4881. PMID 11355880.
- Saha S, Bardelli A, Buckhaults P, et al. (2001). "A phosphatase associated with metastasis of colorectal cancer". Science. 294 (5545): 1343–6. doi:10.1126/science.1065817. PMID 11598267.
- Wang J, Kirby CE, Herbst R (2003). "The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis". J. Biol. Chem. 277 (48): 46659–68. doi:10.1074/jbc.M206407200. PMID 12235145.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Pathak MK, Dhawan D, Lindner DJ, et al. (2003). "Pentamidine is an inhibitor of PRL phosphatases with anticancer activity". Mol. Cancer Ther. 1 (14): 1255–64. PMID 12516958.
- Zeng Q, Dong JM, Guo K, et al. (2003). "PRL-3 and PRL-1 promote cell migration, invasion, and metastasis". Cancer Res. 63 (11): 2716–22. PMID 12782572.
- Bardelli A, Saha S, Sager JA, et al. (2004). "PRL-3 expression in metastatic cancers". Clin. Cancer Res. 9 (15): 5607–15. PMID 14654542.
- Kozlov G, Cheng J, Ziomek E, et al. (2004). "Structural insights into molecular function of the metastasis-associated phosphatase PRL-3". J. Biol. Chem. 279 (12): 11882–9. doi:10.1074/jbc.M312905200. PMID 14704153.
- Kim KA, Song JS, Jee J, et al. (2004). "Structure of human PRL-3, the phosphatase associated with cancer metastasis". FEBS Lett. 565 (1–3): 181–7. doi:10.1016/j.febslet.2004.03.062. PMID 15135076.
- Wu X, Zeng H, Zhang X, et al. (2004). "Phosphatase of Regenerating Liver-3 Promotes Motility and Metastasis of Mouse Melanoma Cells". Am. J. Pathol. 164 (6): 2039–54. doi:10.1016/S0002-9440(10)63763-7. PMC 1615773. PMID 15161639.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Kato H, Semba S, Miskad UA, et al. (2005). "High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases". Clin. Cancer Res. 10 (21): 7318–28. doi:10.1158/1078-0432.CCR-04-0485. PMID 15534108.
- Li J, Guo K, Koh VW, et al. (2005). "Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases". Clin. Cancer Res. 11 (6): 2195–204. doi:10.1158/1078-0432.CCR-04-1984. PMID 15788667.
- Polato F, Codegoni A, Fruscio R, et al. (2006). "PRL-3 phosphatase is implicated in ovarian cancer growth". Clin. Cancer Res. 11 (19 Pt 1): 6835–9. doi:10.1158/1078-0432.CCR-04-2357. PMID 16203771.
- Peng L, Jin G, Wang L, et al. (2006). "Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3". Biochem. Biophys. Res. Commun. 342 (1): 179–83. doi:10.1016/j.bbrc.2006.01.102. PMID 16472776.
- Rouleau C, Roy A, St Martin T, et al. (2006). "Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function". Mol. Cancer Ther. 5 (2): 219–29. doi:10.1158/1535-7163.MCT-05-0289. PMID 16505094.
- Radke I, Götte M, Kersting C, et al. (2006). "Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer". Br. J. Cancer. 95 (3): 347–54. doi:10.1038/sj.bjc.6603261. PMC 2360632. PMID 16832410.